Eli Lilly CEO Comments on Foundayo Spark Optimism Among Investors
Eli Lilly's stock has risen over 18% since April 30, outperforming the S&P 500. During a conference call following Q1 results, CEO David Ricks expressed optimism about their new FDA-approved weight loss drug Foundayo, which is easier to administer than Zepbound and shows strong early momentum.
Tickers: $LLY
Topics: Eli Lilly FDA approval Foundayo stock performance Zepbound